Meeting
2016 Gastrointestinal Cancers Symposium
S-1 in combination with docetaxel and oxaliplatin (DOS) every 2 weeks (DOS2w) or every 3 weeks (DOS3w) in patients with advanced gastro-esophageal adenocarcinoma (aGEA): Final results of 2 parallel phase I studies.
Authors
Camilla Qvortrup
Department of Oncology, Odense University Hospital, Odense, Denmark
Camilla Qvortrup , Jon Kroll Bjerregaard , Per Pfeiffer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
2011-003471-11
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 153)
DOI
10.1200/jco.2016.34.4_suppl.153
Abstract #
153
Poster Bd #
N1
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Results of neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fuluorouracil for advanced esophageal cancer.
First Author: Manabu Emi
Poster
2015 ASCO Annual Meeting
Phase 1 study of the folic acid (FA) and tubulysin B hydrazide (TubBH) small molecule drug conjugate (SMDC) EC1456 in patients (pts) with advanced cancers (CA).
First Author: Daniela Matei
Poster
2015 Gastrointestinal Cancers Symposium
A phase I, dose-finding study of orally administered S-1 in combination with epirubicin and oxaliplatin (EOS) in patients (pts) with advanced or metastatic gastrointestinal cancer (AGIC) and chemonaïve advanced esophagogastric cancer (AEGC).
First Author: Markus Hermann Moehler
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca